SynthesisBMC oral health2026
Dental implant outcomes in patients with diabetes mellitus: a systematic review.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review aimed to evaluate the outcomes of dental implant therapy in patients with diabetes mellitus (DM), focusing on survival rates, peri-implant health, the impact of glycemic control, and the efficacy of adjunctive therapies.
methodsFollowing PRISMA 2020 guidelines, a comprehensive search of multiple databases was conducted up to July 2025. Included studies reported on implant outcomes in diabetic patients or relevant animal models. The methodological quality of the included studies was assessed using appropriate tools such as CONSORT, STROBE, and ARRIVE checklists.
resultsOut of 3,637 identified records, 54 studies were included. While overall implant survival rates in diabetic patients were often high (> 90-95%), diabetes, particularly when poorly controlled (HbA1c > 8%), was consistently associated with significantly worse outcomes. These included greater marginal bone loss (MBL), higher probing depths, increased bleeding on probing, and elevated levels of peri-implant inflammatory markers (e.g., IL-6, TNF-α) compared to non-diabetic controls. Well-controlled diabetics (HbA1c ≤ 7%) often had outcomes comparable to non-diabetics. Adjunctive antimicrobial photodynamic therapy (aPDT) proved effective in improving clinical parameters and reducing inflammation. Preclinical studies on advanced implant surfaces, such as bioactive coatings and 3D-printed porous structures, showed enhanced osseointegration in diabetic conditions.
conclusionDental implant therapy can be successful in well-controlled diabetic patients. However, poor glycemic control significantly increases the risk of peri-implant complications and failure. Successful long-term outcomes necessitate stringent glycemic control, meticulous treatment planning, aggressive maintenance, and the potential application of advanced adjunctive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.